IVX-A12

BIOLOGICAL3 trials

Sponsors

AstraZeneca AB, Icosavax Inc., Icosavax, Inc.

Conditions

HealthyHealthy ParticipantsRespiratory Syncytial Virus and Human Metapneumovirus

Phase 2

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

CompletedNCT05903183

Icosavax, Inc.Healthy

Start: 2023-05-15End: 2024-10-25Updated: 2025-12-05

A Study of IVX-A12 in Adults Participants

CompletedNCT06481579

Icosavax, Inc.Healthy Participants

Start: 2024-06-10End: 2024-12-19Updated: 2025-08-26

Phase 3

A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.

Not yet recruitingCTIS2024-513740-28-00

AstraZeneca AB, Icosavax Inc.Respiratory Syncytial Virus and Human Metapneumovirus

Target: 3714Updated: 2024-11-18

Related Papers

A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age

Open Forum Infectious Diseases2025-03-1313 citations

P-601. Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-like Particle Protein Subunit Combination Vaccine in 60–85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial

Open Forum Infectious Diseases2025-01-291 citations